Possibility of a 2nd EUA application as justification to proceed with the Cantor stock sale ? That seems inevitable given the Hercules debt is secured by the assets and there is nothing to sell except more shares.
I'm not refuting what Scrip says they were told. The person I spoke to gave me an estimate of enrollment, and did not express confidence in the NIH trial being completed before the end of the year. But, if the NIH does an interim review, based on a current enrollment which could currently be between 250-300 patients, then the trial could very well go longer, unless it is stopped because the efficacy we reported is verified. That's what we're all hoping for.
Market Data 
Markets 
AI
